Immuno-Oncology | Specialty

Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer

August 29th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Expert Highlights Potential of Immunotherapy in Gastric Cancer

August 29th 2016

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

August 26th 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Dr. Suresh S. Ramalingam on Optimizing Immunotherapies in Lung Cancer

August 26th 2016

Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

August 26th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma

August 25th 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Immunotherapy Advances Offer New Hope in Bladder Cancer

August 24th 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.

Expert Says Nivolumab Poised to Change Standard of Care in SCCHN

August 23rd 2016

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.

Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment

August 21st 2016

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer

August 15th 2016

Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.

Investigator Highlights Remarkable Responses With Pembrolizumab in Sarcoma

August 12th 2016

Treatment with pembrolizumab (Keytruda) led to a reduction of tumor size in 33% of patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Immunotherapy Transforms Melanoma Care, But Challenges Remain

August 12th 2016

Norman E. Sharpless, MD, discusses the impact of the CheckMate-069 trial, the toxicities that are associated with nivolumab (Opdivo)/ipilimumab (Yervoy), and what the future holds for immunotherapy combinations in the field of melanoma.

Bunn Discusses Frontline Nivolumab NSCLC Results, Issues With PFS Endpoint

August 11th 2016

Paul A. Bunn Jr, MD, discusses the meaning of the CheckMate-026 results with frontline nivolumab in NSCLC and issues with the trial's primary endpoint of progression-free survival.

Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer

August 11th 2016

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

Optimal Therapy Sequence Continues to Evolve for Advanced NSCLC

August 9th 2016

The past few years have seen rapid evolution in the treatment and handling of advanced non–small cell lung cancer, prompting questions on how to optimize immunotherapies and targeted agents as well as incorporate biomarker testing.